Loading…

Targeting DNA methylation in diabetic kidney disease: A new perspective

Diabetic kidney disease (DKD) is a leading diabetic complication causing significant mortality among people around the globe. People with poor glycemic control accompanied by hyperinsulinemia, dyslipidemia, hypertension, and obesity develop diabetic complications. These diabetic patients develop epi...

Full description

Saved in:
Bibliographic Details
Published in:Life sciences (1973) 2023-12, Vol.335, p.122256-122256, Article 122256
Main Authors: Akhouri, Vivek, Majumder, Syamantak, Gaikwad, Anil Bhanudas
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c278t-222575732c24d207ec172e73060e56cb4ecda753b35c79737eb97e71d7b3abc63
cites cdi_FETCH-LOGICAL-c278t-222575732c24d207ec172e73060e56cb4ecda753b35c79737eb97e71d7b3abc63
container_end_page 122256
container_issue
container_start_page 122256
container_title Life sciences (1973)
container_volume 335
creator Akhouri, Vivek
Majumder, Syamantak
Gaikwad, Anil Bhanudas
description Diabetic kidney disease (DKD) is a leading diabetic complication causing significant mortality among people around the globe. People with poor glycemic control accompanied by hyperinsulinemia, dyslipidemia, hypertension, and obesity develop diabetic complications. These diabetic patients develop epigenetic changes and suffer from diabetic kidney complications even after subsequent glucose control, the phenomenon that is recognized as metabolic memory. DNA methylation is an essential epigenetic modification that contributes to the development and progression of several diabetic complications, including DKD. The aberrant DNA methylation pattern at CpGs sites within several genes, such as mTOR, RPTOR, IRS2, GRK5, SLC27A3, LCAT, and SLC1A5, associated with the accompanying risk factors exacerbate the DKD progression. Although drugs such as azacytidine and decitabine have been approved to target DNA methylation for diseases such as hematological malignancies, none have been approved for the treatment of DKD. More importantly, no DNA hypomethylation-targeting drugs have been approved for any disease conditions. Understanding the alteration in DNA methylation and its association with the disease risk factors is essential to target DKD effectively. This review has discussed the abnormal DNA methylation pattern and the kidney tissue-specific expression of critical genes involved in DKD onset and progression. Moreover, we also discuss the new possible therapeutic approach that can be exploited for treating DNA methylation aberrancy in a site-specific manner against DKD.
doi_str_mv 10.1016/j.lfs.2023.122256
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2889239571</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2889239571</sourcerecordid><originalsourceid>FETCH-LOGICAL-c278t-222575732c24d207ec172e73060e56cb4ecda753b35c79737eb97e71d7b3abc63</originalsourceid><addsrcrecordid>eNotkMFOwzAQRC0EEqXwAdx85JJgr-tswq0qUJAquJSz5Tjb4pImwU5B-XtSldNoNKPZ1WPsVopUCpnd79J6E1MQoFIJADo7YxOZY5GITMlzNhECZokCoS_ZVYw7IYTWqCZsubZhS71vtvzxbc731H8Ote1923Df8Mrbcgwd__JVQ8PoI9lID3zOG_rlHYXYkev9D12zi42tI93865R9PD-tFy_J6n35upivEgeY98nxNRwPg4NZBQLJSQRCJTJBOnPljFxlUatSaYcFKqSyQEJZYals6TI1ZXen3S603weKvdn76KiubUPtIRrI8wJUoVGOVXmqutDGGGhjuuD3NgxGCnOEZnZmhGaO0MwJmvoDLKFfpg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2889239571</pqid></control><display><type>article</type><title>Targeting DNA methylation in diabetic kidney disease: A new perspective</title><source>ScienceDirect Journals</source><creator>Akhouri, Vivek ; Majumder, Syamantak ; Gaikwad, Anil Bhanudas</creator><creatorcontrib>Akhouri, Vivek ; Majumder, Syamantak ; Gaikwad, Anil Bhanudas</creatorcontrib><description>Diabetic kidney disease (DKD) is a leading diabetic complication causing significant mortality among people around the globe. People with poor glycemic control accompanied by hyperinsulinemia, dyslipidemia, hypertension, and obesity develop diabetic complications. These diabetic patients develop epigenetic changes and suffer from diabetic kidney complications even after subsequent glucose control, the phenomenon that is recognized as metabolic memory. DNA methylation is an essential epigenetic modification that contributes to the development and progression of several diabetic complications, including DKD. The aberrant DNA methylation pattern at CpGs sites within several genes, such as mTOR, RPTOR, IRS2, GRK5, SLC27A3, LCAT, and SLC1A5, associated with the accompanying risk factors exacerbate the DKD progression. Although drugs such as azacytidine and decitabine have been approved to target DNA methylation for diseases such as hematological malignancies, none have been approved for the treatment of DKD. More importantly, no DNA hypomethylation-targeting drugs have been approved for any disease conditions. Understanding the alteration in DNA methylation and its association with the disease risk factors is essential to target DKD effectively. This review has discussed the abnormal DNA methylation pattern and the kidney tissue-specific expression of critical genes involved in DKD onset and progression. Moreover, we also discuss the new possible therapeutic approach that can be exploited for treating DNA methylation aberrancy in a site-specific manner against DKD.</description><identifier>ISSN: 0024-3205</identifier><identifier>EISSN: 1879-0631</identifier><identifier>DOI: 10.1016/j.lfs.2023.122256</identifier><language>eng</language><ispartof>Life sciences (1973), 2023-12, Vol.335, p.122256-122256, Article 122256</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c278t-222575732c24d207ec172e73060e56cb4ecda753b35c79737eb97e71d7b3abc63</citedby><cites>FETCH-LOGICAL-c278t-222575732c24d207ec172e73060e56cb4ecda753b35c79737eb97e71d7b3abc63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Akhouri, Vivek</creatorcontrib><creatorcontrib>Majumder, Syamantak</creatorcontrib><creatorcontrib>Gaikwad, Anil Bhanudas</creatorcontrib><title>Targeting DNA methylation in diabetic kidney disease: A new perspective</title><title>Life sciences (1973)</title><description>Diabetic kidney disease (DKD) is a leading diabetic complication causing significant mortality among people around the globe. People with poor glycemic control accompanied by hyperinsulinemia, dyslipidemia, hypertension, and obesity develop diabetic complications. These diabetic patients develop epigenetic changes and suffer from diabetic kidney complications even after subsequent glucose control, the phenomenon that is recognized as metabolic memory. DNA methylation is an essential epigenetic modification that contributes to the development and progression of several diabetic complications, including DKD. The aberrant DNA methylation pattern at CpGs sites within several genes, such as mTOR, RPTOR, IRS2, GRK5, SLC27A3, LCAT, and SLC1A5, associated with the accompanying risk factors exacerbate the DKD progression. Although drugs such as azacytidine and decitabine have been approved to target DNA methylation for diseases such as hematological malignancies, none have been approved for the treatment of DKD. More importantly, no DNA hypomethylation-targeting drugs have been approved for any disease conditions. Understanding the alteration in DNA methylation and its association with the disease risk factors is essential to target DKD effectively. This review has discussed the abnormal DNA methylation pattern and the kidney tissue-specific expression of critical genes involved in DKD onset and progression. Moreover, we also discuss the new possible therapeutic approach that can be exploited for treating DNA methylation aberrancy in a site-specific manner against DKD.</description><issn>0024-3205</issn><issn>1879-0631</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNotkMFOwzAQRC0EEqXwAdx85JJgr-tswq0qUJAquJSz5Tjb4pImwU5B-XtSldNoNKPZ1WPsVopUCpnd79J6E1MQoFIJADo7YxOZY5GITMlzNhECZokCoS_ZVYw7IYTWqCZsubZhS71vtvzxbc731H8Ote1923Df8Mrbcgwd__JVQ8PoI9lID3zOG_rlHYXYkev9D12zi42tI93865R9PD-tFy_J6n35upivEgeY98nxNRwPg4NZBQLJSQRCJTJBOnPljFxlUatSaYcFKqSyQEJZYals6TI1ZXen3S603weKvdn76KiubUPtIRrI8wJUoVGOVXmqutDGGGhjuuD3NgxGCnOEZnZmhGaO0MwJmvoDLKFfpg</recordid><startdate>20231215</startdate><enddate>20231215</enddate><creator>Akhouri, Vivek</creator><creator>Majumder, Syamantak</creator><creator>Gaikwad, Anil Bhanudas</creator><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20231215</creationdate><title>Targeting DNA methylation in diabetic kidney disease: A new perspective</title><author>Akhouri, Vivek ; Majumder, Syamantak ; Gaikwad, Anil Bhanudas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c278t-222575732c24d207ec172e73060e56cb4ecda753b35c79737eb97e71d7b3abc63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Akhouri, Vivek</creatorcontrib><creatorcontrib>Majumder, Syamantak</creatorcontrib><creatorcontrib>Gaikwad, Anil Bhanudas</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Life sciences (1973)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Akhouri, Vivek</au><au>Majumder, Syamantak</au><au>Gaikwad, Anil Bhanudas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeting DNA methylation in diabetic kidney disease: A new perspective</atitle><jtitle>Life sciences (1973)</jtitle><date>2023-12-15</date><risdate>2023</risdate><volume>335</volume><spage>122256</spage><epage>122256</epage><pages>122256-122256</pages><artnum>122256</artnum><issn>0024-3205</issn><eissn>1879-0631</eissn><abstract>Diabetic kidney disease (DKD) is a leading diabetic complication causing significant mortality among people around the globe. People with poor glycemic control accompanied by hyperinsulinemia, dyslipidemia, hypertension, and obesity develop diabetic complications. These diabetic patients develop epigenetic changes and suffer from diabetic kidney complications even after subsequent glucose control, the phenomenon that is recognized as metabolic memory. DNA methylation is an essential epigenetic modification that contributes to the development and progression of several diabetic complications, including DKD. The aberrant DNA methylation pattern at CpGs sites within several genes, such as mTOR, RPTOR, IRS2, GRK5, SLC27A3, LCAT, and SLC1A5, associated with the accompanying risk factors exacerbate the DKD progression. Although drugs such as azacytidine and decitabine have been approved to target DNA methylation for diseases such as hematological malignancies, none have been approved for the treatment of DKD. More importantly, no DNA hypomethylation-targeting drugs have been approved for any disease conditions. Understanding the alteration in DNA methylation and its association with the disease risk factors is essential to target DKD effectively. This review has discussed the abnormal DNA methylation pattern and the kidney tissue-specific expression of critical genes involved in DKD onset and progression. Moreover, we also discuss the new possible therapeutic approach that can be exploited for treating DNA methylation aberrancy in a site-specific manner against DKD.</abstract><doi>10.1016/j.lfs.2023.122256</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0024-3205
ispartof Life sciences (1973), 2023-12, Vol.335, p.122256-122256, Article 122256
issn 0024-3205
1879-0631
language eng
recordid cdi_proquest_miscellaneous_2889239571
source ScienceDirect Journals
title Targeting DNA methylation in diabetic kidney disease: A new perspective
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T17%3A32%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeting%20DNA%20methylation%20in%20diabetic%20kidney%20disease:%20A%20new%20perspective&rft.jtitle=Life%20sciences%20(1973)&rft.au=Akhouri,%20Vivek&rft.date=2023-12-15&rft.volume=335&rft.spage=122256&rft.epage=122256&rft.pages=122256-122256&rft.artnum=122256&rft.issn=0024-3205&rft.eissn=1879-0631&rft_id=info:doi/10.1016/j.lfs.2023.122256&rft_dat=%3Cproquest_cross%3E2889239571%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c278t-222575732c24d207ec172e73060e56cb4ecda753b35c79737eb97e71d7b3abc63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2889239571&rft_id=info:pmid/&rfr_iscdi=true